Santen Pharmaceutical Correlations
| SNPHF Stock | USD 10.53 0.62 5.56% |
The current 90-days correlation between Santen Pharmaceutical and Ono Pharmaceutical Co is -0.01 (i.e., Good diversification). The correlation of Santen Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Santen Pharmaceutical Correlation With Market
Significant diversification
The correlation between Santen Pharmaceutical Co and DJI is 0.08 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Santen Pharmaceutical Co and DJI in the same portfolio, assuming nothing else is changed.
Santen |
The ability to find closely correlated positions to Santen Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Santen Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Santen Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Santen Pharmaceutical Co to buy it.
Moving together with Santen Pink Sheet
| 0.7 | RHHBF | Roche Holding AG | PairCorr |
| 0.64 | RHHBY | Roche Holding | PairCorr |
| 0.61 | RHHVF | Roche Holding AG | PairCorr |
Moving against Santen Pink Sheet
| 0.55 | NFLX | Netflix Fiscal Year End 28th of January 2025 | PairCorr |
| 0.53 | BBAI | BigBearai Holdings Tech Boost | PairCorr |
| 0.44 | RUM | Rumble Inc Sell-off Trend | PairCorr |
| 0.4 | PYPL | PayPal Holdings Aggressive Push | PairCorr |
| 0.69 | ET | Energy Transfer LP Aggressive Push | PairCorr |
| 0.66 | LUNR | Intuitive Machines | PairCorr |
| 0.63 | BFLY | Butterfly Network | PairCorr |
| 0.57 | APLD | Applied Blockchain | PairCorr |
| 0.56 | CRS | Carpenter Technology | PairCorr |
| 0.52 | IONQ | IONQ Inc | PairCorr |
| 0.51 | SOFI | SoFi Technologies | PairCorr |
| 0.5 | PLTR | Palantir Technologies Aggressive Push | PairCorr |
| 0.48 | BAC | Bank of America Fiscal Year End 10th of January 2025 | PairCorr |
| 0.4 | SOUN | SoundHound AI Trending | PairCorr |
| 0.39 | FUND | Sprott Focus Trust | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Risk-Adjusted Indicators
There is a big difference between Santen Pink Sheet performing well and Santen Pharmaceutical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Santen Pharmaceutical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| OPHLY | 1.22 | (0.26) | 0.00 | 2.74 | 0.00 | 2.09 | 10.36 | |||
| GLAXF | 1.97 | (0.33) | 0.00 | (1.81) | 0.00 | 4.48 | 15.33 | |||
| GRFS | 2.13 | (0.10) | 0.00 | (0.71) | 0.00 | 5.57 | 22.90 | |||
| PFE | 1.06 | (0.25) | 0.00 | (0.93) | 0.00 | 2.07 | 8.17 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Santen Pharmaceutical without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Share Portfolio Now
Share PortfolioTrack or share privately all of your investments from the convenience of any device |
| All Next | Launch Module |
Santen Pharmaceutical Corporate Management
| Nobuko Kato | Chief Officer | Profile | |
| Mika Masunari | G Officer | Profile | |
| Nikolas Tripodis | Chief Officer | Profile | |
| Kaori Itagaki | Gen Group | Profile |